Announcements
Sidley Represents Clearlake Capital in Strategic Investment in Aptean
July 23, 2024
Sidley represented Clearlake Capital Group, L.P. in its strategic investment in Aptean, a global provider of customer relationship management solutions, enterprise resource planning software for manufacturing companies, and supply chain applications. Clearlake joins existing investors TA Associates, Insight Partners, and Charlesbank Capital Partners to enable Aptean’s management team to continue delivering differentiated solutions to the market and accelerate the company’s growth.
The Sidley team was led by Mehdi Khodadad and Mark Castiglia (M&A and Private Equity) and included Anthony James Friedman (M&A and Private Equity); Vadim Brusser and Ken Daly (Antitrust and Competition); Eric Kauffman (Labor, Employment and Immigration); Stacy Crosnicker (Employee Benefits & Executive Compensation); Sven De Knop and Alessandra Moroni (International Trade); and Rachel Kleinberg and Jonathan Westreich (Tax).
The Sidley team was led by Mehdi Khodadad and Mark Castiglia (M&A and Private Equity) and included Anthony James Friedman (M&A and Private Equity); Vadim Brusser and Ken Daly (Antitrust and Competition); Eric Kauffman (Labor, Employment and Immigration); Stacy Crosnicker (Employee Benefits & Executive Compensation); Sven De Knop and Alessandra Moroni (International Trade); and Rachel Kleinberg and Jonathan Westreich (Tax).
連絡先
得意分野
Suggested News & Insights
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private PlacementJuly 17, 2026Sidley Finishes H1 2026 Among Top Three US$1B+ Dealmakers in TexasJuly 16, 2026European Commission Signals Targeted Procedural Simplification of the Foreign Subsidies Regulation – Without Weakening EnforcementJuly 16, 2026Inspection Rights, Internal Affairs, and Personal Jurisdiction: Orchid Global’s Procedural LessonJuly 15, 2026Sidley Advises EMZ Partners on Its Significant Minority Investment in Steinbach & VollmannJuly 13, 2026Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZenecaJuly 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory





